April 22, 2021 -- Vaxess Technologies announced it has received a $2.9 million grant from the National Institute of Allergy and Infectious Diseases, an agency of the U.S. National Institutes of Health (NIH), to evaluate and commercialize a method for delivering vaccines through a next-generation, sustained-release intradermal microneedle patch.
The patch mimics natural infection kinetics using sustained-release microneedles implanted in a patient's dermal barrier. The controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, which ultimately boosts a vaccine's effectiveness, according to the company.
Originally conceived at the Massachusetts Institute of Technology and Tufts University, the technology utilizes the unique qualities of silk proteins and mechanisms involved in immune system activation.
Copyright © 2021 scienceboard.net